Command Palette

Search for a command to run...

All RADS systems

O-RADS US

Ultrasound risk stratification of ovarian and adnexal lesions (ovaries, lesions involving or suspected to involve the ovaries or fallopian tubes, and paraovarian cysts) when the intent is to stratify malignancy risk. Using a standardized lexicon (lesion type, locularity, inner wall or outer contour, size, solid tissue, and color score), assign O-RADS 0–5 with a risk of malignancy and a management pathway that, for categories 1–2, depends on menopausal status.
v2022·reviewed 2026-10-06
  • Lexicon: smooth/irregular refers to the inner wall or septations of cystic lesions and the outer contour of solid lesions; irregular inner wall = <3 mm in height. A solid component protrudes ≥3 mm; a solid lesion is ≥80% solid (excluding blood products and dermoid contents). Shadowing must be diffuse or broad (not refractive artifact).
  • Management recommendations are guidance for average-risk patients without acute symptoms; they may be modified for personal or family history of ovarian cancer, BRCA mutation, symptoms, and clinical judgment.
  • MRI with contrast has higher specificity for solid lesions and cystic lesions with solid components; O-RADS MRI can problem-solve O-RADS US 3–4 lesions.
  • The simple-cyst intervals here are O-RADS US v2022. The SRU 2019 simple-cyst consensus (`adnexal-cyst-us`) uses different thresholds and visualization-dependent intervals.
How to assign
  1. 1Check that O-RADS applies: not for pelvic inflammatory disease, ectopic pregnancy, torsion of a normal ovary, or lesions clearly non-ovarian/non-tubal (for example, an exophytic or broad-ligament myoma). Absent or non-visualized ovaries are “O-RADS: not applicable”; use O-RADS 0 when an expected ovary is not seen or technical factors prevent assessment of features relevant to risk.
  2. 2Use the single largest diameter for scoring and management (report three dimensions; average linear dimension for interval change). Assess transvaginally where possible.
  3. 3No ovarian lesion, or a follicle (≤3 cm) or corpus luteum (typically ≤3 cm) → O-RADS 1.
  4. 4Typical classic benign lesion (hemorrhagic cyst, dermoid, endometrioma) <10 cm, or a typical extraovarian lesion (paraovarian cyst, peritoneal inclusion cyst, hydrosalpinx) of any size → O-RADS 2, managed per the classic benign lesions table. A typical benign ovarian lesion ≥10 cm → O-RADS 3.
  5. 5Otherwise classify the lesion type: unilocular (no septation), bilocular (one complete septation, 2 locules), multilocular (≥3 locules), cystic with solid component(s), or solid (≥80% solid). Note smooth vs irregular inner wall (cystic) or outer contour (solid), papillary projections (solid component ≥3 mm into the lumen, surrounded by fluid on 3 sides), and shadowing (diffuse or broad).
  6. 6Assign the color score: 1 no flow, 2 minimal, 3 moderate, 4 very strong.
  7. 7Map to the category using the descriptors below. If unsure between two features (for example, smooth vs irregular, or color score), use the higher-risk category. With multiple or bilateral lesions, characterize each; management follows the highest score.
  8. 8Menopausal status: postmenopausal = amenorrhea ≥1 year (early <5 years, late ≥5 years). If uncertain or no uterus, treat age >50 as postmenopausal (early >50 to <55, late ≥55).
0Incomplete evaluationLesion features relevant for risk stratification cannot be accurately characterized because of technical factors (not reader uncertainty). May also be used when an ovary is expected but not seen.

Repeat US study or MRI.

O-RADS US 0. Incomplete evaluation because of technical factors. Recommend repeat ultrasound or MRI.

1Normal ovary0% risk. No ovarian lesion, or a physiologic cyst: follicle ≤3 cm or corpus luteum (typically ≤3 cm).

None.

O-RADS US 1. Normal ovary. No follow-up is needed.

2Almost certainly benign<1% risk. Simple cyst <10 cm; unilocular smooth non-simple cyst (internal echoes and/or incomplete septations) or bilocular smooth cyst <10 cm; typical classic benign ovarian lesion <10 cm; typical extraovarian lesion (paraovarian cyst, peritoneal inclusion cyst, hydrosalpinx) of any size.

Simple cyst: ≤3 cm none; >3–5 cm none (premenopausal) or follow-up US in 12 months (postmenopausal); >5 to <10 cm follow-up US in 12 months. Unilocular smooth non-simple or bilocular smooth cyst: ≤3 cm none (premenopausal) or follow-up US in 12 months (postmenopausal); >3 to <10 cm follow-up US in 6 months. Classic benign lesions: see the classic benign lesions table. If the cyst shrinks by ≥10–15% in average linear dimension, no further surveillance; if stable, consider US at 24 months from the initial exam.

O-RADS US 2 (almost certainly benign, <1% risk of malignancy). Management per lesion type, size, and menopausal status.

3Low risk1 to <10% risk. Typical benign ovarian lesion ≥10 cm; unilocular or bilocular smooth cyst ≥10 cm; unilocular cyst with an irregular inner wall (any size); multilocular smooth cyst <10 cm with color score <4; solid smooth lesion (± shadowing) of any size with color score 1; solid smooth shadowing lesion of any size with color score 2–3.

Imaging: if not surgically excised, consider follow-up US within 6 months; if solid, may consider a US specialist or MRI (with O-RADS MRI score). Clinical: gynecologist.

O-RADS US 3 (low risk, 1 to <10% risk of malignancy). If not surgically excised, consider follow-up ultrasound within 6 months. Gynecology management.

4Intermediate risk10 to <50% risk. Bilocular cyst without solid component with an irregular inner wall (any size, any color score); multilocular cyst without solid component that is smooth ≥10 cm with color score <4, smooth with color score 4 (any size), or irregular (any size, any color score); unilocular cyst with <4 papillary projections or a solid component that is not a papillary projection (any size, any color score); bilocular or multilocular cyst with solid component(s) and color score 1–2; solid smooth non-shadowing lesion with color score 2–3.

Imaging options: US specialist (if available), MRI (with O-RADS MRI score), or per gyn-oncologist protocol. Clinical: gynecologist with gyn-oncologist consultation, or gyn-oncologist alone.

O-RADS US 4 (intermediate risk, 10 to <50% risk of malignancy). Recommend further evaluation by an ultrasound specialist or MRI with O-RADS MRI scoring, and gynecologic oncology involvement.

5High risk≥50% risk. Unilocular cyst with ≥4 papillary projections (any size, any color score); bilocular or multilocular cyst with solid component(s) and color score 3–4; solid smooth lesion (± shadowing) with color score 4; solid lesion with an irregular outer contour (any size, any color score); ascites and/or peritoneal nodules (not due to other malignant or non-malignant causes).

Imaging: per gyn-oncologist protocol. Clinical: gyn-oncologist.

O-RADS US 5 (high risk, ≥50% risk of malignancy). Recommend gynecologic oncology referral.

Sources

  • Strachowski LM, et al. O-RADS US v2022: An Update from the American College of Radiology's Ovarian-Adnexal Reporting and Data System US Committee. Radiology. 2023;308(3):e230685.

Educational reference for clinicians — not medical advice. Verify against the primary source before acting on it; guidelines change. Final decisions rest with the interpreting physician and your institution's protocols.